Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting

The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio-metabolic risk management as a priority, the choice of various combinations of antidiabetic agents should be individualized. Comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Chadha, Manoj, Das, Ashok Kumar, Deb, Prasun, Gangopadhyay, Kalyan Kumar, Joshi, Shashank, Kesavadev, Jothydev, Kovil, Rajiv, Kumar, Surender, Misra, Anoop, Mohan, Viswanathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Practical Approach
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948458/
https://www.ncbi.nlm.nih.gov/pubmed/35334083
http://dx.doi.org/10.1007/s13300-022-01219-x
_version_ 1784674663919517696
author Chadha, Manoj
Das, Ashok Kumar
Deb, Prasun
Gangopadhyay, Kalyan Kumar
Joshi, Shashank
Kesavadev, Jothydev
Kovil, Rajiv
Kumar, Surender
Misra, Anoop
Mohan, Viswanathan
author_facet Chadha, Manoj
Das, Ashok Kumar
Deb, Prasun
Gangopadhyay, Kalyan Kumar
Joshi, Shashank
Kesavadev, Jothydev
Kovil, Rajiv
Kumar, Surender
Misra, Anoop
Mohan, Viswanathan
author_sort Chadha, Manoj
collection PubMed
description The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio-metabolic risk management as a priority, the choice of various combinations of antidiabetic agents should be individualized. Combined therapy with two classes of antidiabetic agents, namely, dipeptidyl peptidase 4 inhibitors and sodium-glucose co-transporter-2 inhibitors, target several pathophysiological pathways. The wide-ranging clinical outcomes associated with this combination, including improvement of glycemia and adiposity, reduction of metabolic and vascular risk, safety, and simplicity for sustainable compliance, are extremely relevant to the Asian Indian patient population living with T2DM. In this review we describe the available evidence in detail and present a rational practical guidance for the optimum clinical use of this combination in this patient population.
format Online
Article
Text
id pubmed-8948458
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-89484582022-03-25 Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting Chadha, Manoj Das, Ashok Kumar Deb, Prasun Gangopadhyay, Kalyan Kumar Joshi, Shashank Kesavadev, Jothydev Kovil, Rajiv Kumar, Surender Misra, Anoop Mohan, Viswanathan Diabetes Ther Practical Approach The Asian-Indian phenotype of type 2 diabetes mellitus is uniquely characterized for cardio-metabolic risk. In the context of implementing patient-centric holistic cardio-metabolic risk management as a priority, the choice of various combinations of antidiabetic agents should be individualized. Combined therapy with two classes of antidiabetic agents, namely, dipeptidyl peptidase 4 inhibitors and sodium-glucose co-transporter-2 inhibitors, target several pathophysiological pathways. The wide-ranging clinical outcomes associated with this combination, including improvement of glycemia and adiposity, reduction of metabolic and vascular risk, safety, and simplicity for sustainable compliance, are extremely relevant to the Asian Indian patient population living with T2DM. In this review we describe the available evidence in detail and present a rational practical guidance for the optimum clinical use of this combination in this patient population. Springer Healthcare 2022-03-25 2022-05 /pmc/articles/PMC8948458/ /pubmed/35334083 http://dx.doi.org/10.1007/s13300-022-01219-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Practical Approach
Chadha, Manoj
Das, Ashok Kumar
Deb, Prasun
Gangopadhyay, Kalyan Kumar
Joshi, Shashank
Kesavadev, Jothydev
Kovil, Rajiv
Kumar, Surender
Misra, Anoop
Mohan, Viswanathan
Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
title Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
title_full Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
title_fullStr Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
title_full_unstemmed Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
title_short Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
title_sort expert opinion: optimum clinical approach to combination-use of sglt2i + dpp4i in the indian diabetes setting
topic Practical Approach
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948458/
https://www.ncbi.nlm.nih.gov/pubmed/35334083
http://dx.doi.org/10.1007/s13300-022-01219-x
work_keys_str_mv AT chadhamanoj expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT dasashokkumar expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT debprasun expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT gangopadhyaykalyankumar expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT joshishashank expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT kesavadevjothydev expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT kovilrajiv expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT kumarsurender expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT misraanoop expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting
AT mohanviswanathan expertopinionoptimumclinicalapproachtocombinationuseofsglt2idpp4iintheindiandiabetessetting

Ejemplares similares